With the PBS subsidy, eligible patients will only need to pay $41 per prescription, or $6.60 with a concession card. This medicine is injected once every two weeks and is not intended for episodic use. Unlike other drugs treatments for eczema, patients are able to administer dupilumab themselves after having received appropriate training from a healthcare professional. A single syringe and needle delivers one dose.
#DUPIXENT MY WAY CARD SKIN#
How is it administered?ĭupilumab is given by injection under the skin once every two weeks. It will not be offered by GP you will need to be referred to see a specialist. If you think you might be eligible for dupilumab, speak to your Dermatologist or Immunologist about the possibility of trying it. Who is it for?ĭupilumab is licensed for the treatment of children from 6 years of age and adults with moderate-to-severe atopic dermatitis (atopic eczema) who are possible candidates for systemic therapy who have failed to respond to optimally prescribed topical treatments.
#DUPIXENT MY WAY CARD TRIAL#
The trial data results showed that many patients taking dupilumab no longer needed to apply as much topical steroid while taking the drug. Many patients receiving dupliumab also experience a reduction in itching and an improvement in sleep and quality of life. What has the research shown?Ĭlinical trials of dupilumab have shown that it produces a meaningful reduction in the severity of eczema, as well as a reduction in the body surface affected by eczema in the majority of patients. Immunosuppressive drugs for eczema (eg ciclosporin) suppress many different chemical messengers that control inflammation, whereas biologic drugs suppress just one or two of these chemical messengers and have fewer potential side effects than conventional immunosuppressive drugs. If you think of a chemical messenger such as IL-4 as a key, and a cell receptor as lock, a biologic drug works in a similar way to fixing a coin over the keyhole so that the key (IL-4) is unable to get into the lock (the cell receptor). By Blocking IL-4 and IL-13 from binding to their cell receptors, dupilumab limits to the overreaction of the immune system, dampening down the chronic inflammatory response and lessening the symptoms of atopic eczema. Dupilumab works on two specific ILs thought to contribute to atopic conditions: IL-4 and IL-13. It is this chronic inflammation that leads to symptoms of eczema such as red, itchy, dry patches on the skin.īiologics works by blocking ILs from binding to their cell receptors (protein molecules that receive chemical signals from outside a cell) this stops the immune system from overreacting. This triggers the production of certain ILs, which cause greater inflammation. The immune system of people with inflammatory conditions like atopic eczema overreacts to allergens (eg dust, mould, pollen). How does it work?Ĭhemical messengers in the body called interleukins (ILs) allow the different parts of our immune system to communicate and help fight off harmful viruses and bacteria.
There are other biologic treatments for atopic eczema that are currently undergoing research. Dupilumab is the first biologic treatment for atopic eczema and is taken subcutaneously (under the skin). Biologic drugs are produced by genetically modified organisms such as bacteria or cells cultured in a laboratory. Dupilumab (Dupixent®) A new biologic treatment for atopic eczema offers real hope to those living with more severe eczemaĭupilumab* (Dupixent®) is a new ‘biologic’ treatment for severe eczema which works in a different way to the other drugs that are currently available for eczema.
0 kommentar(er)
